Quantum BioPharma signed an agreement to start services for the Lucid-MS Phase 2 trial. This advances testing in people, but the study still needs to show safety and benefit.
This gives Lucid-MS a path into a Phase 2 test in people, an important step for Quantum BioPharma. The study still needs to show whether patients tolerate the drug and whether it helps them. Earlier preclinical studies found it could prevent and reverse signs of myelin damage. Those results offer support, but they do not show that the drug works in people.
Thermo Fisher's research unit will provide study-startup and related trial services for Quantum BioPharma. The story gives no contract value or wider business effect, so it does not change the outlook for Thermo Fisher.
Follow Quantum BioPharma Ltd. (QNTM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for QNTM